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Abstract
Schizophrenia, a devastating psychiatric disorder, has a prevalence of 0.5–1%, with high
heritability (80–85%) and complex transmission.1 Recent studies implicate rare, large, high-
penetrance copy number variants (CNVs) in some cases2, but it is not known what genes or
biological mechanisms underlie susceptibility. Here we show that schizophrenia is significantly
associated with single nucleotide polymorphisms (SNPs) in the extended Major
Histocompatibility Complex (MHC) region on chromosome 6. We carried out a genome-wide
association study (GWAS) of common SNPs in the Molecular Genetics of Schizophrenia (MGS)
case-control sample, and then a meta-analysis of data from the MGS, International Schizophrenia
Consortium (ISC) and SGENE datasets. No MGS finding achieved genome-wide statistical
significance. In the meta-analysis of European-ancestry subjects (8,008 cases, 19,077 controls),
significant association with schizophrenia was observed in a region of linkage disequilibrium on
chromosome 6p22.1 (P = 9.54 × 10−9). This region includes a histone gene cluster and several
immunity-related genes, possibly implicating etiologic mechanisms involving chromatin
modification, transcriptional regulation, auto-immunity and/or infection. These results
demonstrate that common schizophrenia susceptibility alleles can be detected. The
characterization of these signals will suggest important directions for research on susceptibility
mechanisms.
The symptoms and course of schizophrenia are variable, without forming distinct familial
subtypes.1 There are positive (delusions, hallucinations), negative (reduced emotions,
speech, interest) and disorganized symptoms (disrupted syntax and behavior), as well as
mood symptoms in many cases. Onset is typically in adolescence or early adulthood, and
rarely in childhood. Course of illness can range from acute episodes with primarily positive
symptoms to the more common chronic or relapsing patterns often accompanied by
cognitive disability and histories of childhood conduct or developmental disorders.
To search for common schizophrenia susceptibility variants, we carried out a GWAS in
cases from three methodologically similar National Institute of Mental Health repository-
based studies, and screened controls from the general population. Cases were included with
diagnoses of schizophrenia or (in 10% of cases) schizoaffective disorder with the
schizophrenia syndrome present for at least six months, genotyped with the Affymetrix 6.0
array. Because the frequencies of tag SNPs and disease susceptibility alleles can vary across
populations, we carried out a primary analysis of the larger MGS European-ancestry sample
(2,681 cases, 2,653 controls) and then additional analyses of the African American sample
(1,286 cases, 973 controls) and of both of these samples combined, to test the hypothesis
that there are alleles that influence susceptibility in both populations. All association tests
were corrected using principal component scores indexing subjects’ ancestral origins.
Genotypic data were imputed for additional HapMap SNPs in selected regions.
Shi et al. Page 2
Nature. Author manuscript; available in PMC 2010 February 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
These analyses did not produce genome-wide significant findings at a threshold of P < 5 ×
10−8 (see Supplementary Methods, p. S16). Table 1 summarizes the best results in the
European-ancestry and African American analyses. The strongest genic findings were in
CENTG2 (chromosome 2q37.2, P=4.59E-07) in European-ancestry subjects, and in ERBB4
(2q34, P=2.14E-06) in African Americans. Common variants in ERBB4 (the strongest
signal in African American subjects) and its ligand neuregulin 1 (NRG1) have been reported
to be associated with schizophrenia.3 Additional information about results in previously-
reported schizophrenia candidate genes is provided in Supplementary Results 3 and
Supplementary Datafile 2.
As shown in online Table S17, power was adequate in the MGS European-ancestry sample
to detect very common risk alleles (30–60% frequency, log additive effects) with genotypic
relative risks (GRR) of approximately 1.3, with lower power in the smaller African
American sample. The results suggest that there are few or no single common loci with such
large effects on risk. The lack of consistency between the European-ancestry and African
American analyses could be due to low power, but novel genome-wide analyses presented in
the companion paper by the International Schizophrenia Consortium (discussed further
below) suggest that while there is substantial overlap between the sets of risk alleles that are
detected by GWAS in pairs of European-ancestry samples, much less overlap is seen
between European-ancestry and African American samples. This could be because there are
actually major differences between the sets of segregating common disease variants in these
two populations, and/or because many risk variants are tagged by different GWAS markers
or not adequately tagged by the GWAS array, which has poorer coverage of alleles that are
more frequent in African populations. The hypothesis underlying our combined analysis, on
the other hand, was that there could also be allelic effects common to these populations.
For many common diseases, common risk alleles with GRRs in the range of 1.1–1.2 have
been detected when samples were combined to create much larger datasets.4 Therefore, we
carried out a meta-analysis of European-ancestry data with two other large studies: the
International Schizophrenia Consortium (ISC) (3,322 cases, 3,587 controls) and the SGENE
Consortium (2,005 cases, 12,837 controls). Note that because the Aberdeen sample was part
of both the ISC and SGENE consortia, Aberdeen data were excluded from SGENE
association tests for the meta-analysis. To rapidly identify the regions containing the
strongest findings across the three studies (which used several Affymetrix and Illumina
genotyping platforms), each group created a list of the SNPs with the best P-values in its
final analysis (e.g., those with P<0.001 in MGS), and provided the other groups with its P-
values for the SNPs on their lists, based on genotyped or imputed data or data for the best
proxy based on LD. Based on these initial results, all available data for genotyped SNPs and
imputed HapMap II SNPs were then shared for regions of interest, of which four emerged
from the European-ancestry data: 1p21.3 (PTBP2), 4q33 (NEK1), 6p22.1-6p21.31 (extended
MHC region) and 18q21.2 (TCF4). We then combined P-values for all SNPs in each region
by appropriately weighting Z-scores for sample size, accounting for the direction of
association in each sample.
In the meta-analysis of European-ancestry MGS, ISC and SGENE datasets, seven SNPs on
chromosome 6p22.1 yielded genome-wide significant evidence for association. These SNPs
span 209 kb and are in strong LD (r2>0.9), with substantial LD across 1.5 Mb (Table 2 and
Figure 1). Because of the strong LD among these SNPs, it is unclear whether the signal is
driven by one or several genes, by intergenic elements, or by longer haplotypes that include
susceptibility alleles in many genes. The region includes several types of genes of potential
interest. The strongest evidence for association was observed in and near a cluster of histone
protein genes, which could be relevant to schizophrenia through their roles in regulation of
DNA transcription and repair5,6 or their direct role in antimicrobial defense.7 Other genes
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in the broad region are involved in chromatin structure (HMGN4), transcriptional regulation
(ABT1, ZNF322A, ZNF184), immunity (PRSS16; the butyrophilins8), G-protein-coupled
receptor signaling (FKSG83) and in the nuclear pore complex (POM121L2), although the
functions of many genes in the region (and of intergenic sequence variants) are not well
understood.
P-values less than 10−7 were also observed in the meta-analysis in HLA-DQA1 (P = 6.88 ×
10−8, Table 2), suggesting autoimmune mechanisms. This gene is in the class II HLA
region, which is not in LD with 6p22.1 in the MGS sample. We note also that the MGS
GWAS (see Supplementary Datafile 1, European-ancestry results) produced some evidence
for association in the FAM69A-EVI-RPL5 gene cluster which has been implicated in
multiple sclerosis, a DQA-associated auto-immune disorder.9
Finally, in an analysis reported in the companion paper by the International Schizophrenia
Consortium, case-control status in the MGS sample could be predicted with very strong
statistical significance based on an aggregate test of large numbers of common alleles,
weighted by their odds ratios in the single-SNP association analysis of the ISC sample
(please see the ISC paper for details). As expected, results were similar for an analysis with
MGS as the discovery sample and ISC as the target (see Supplementary Results 3). As
discussed in the ISC paper, the results suggest that a substantial proportion of variance may
be explained by many common variants, most of them with small effects that cannot be
detected one at a time.
We have identified a region of association of common SNPs with schizophrenia on
chromosome 6p22.1. Further research will be required to identify the sequence variation in
this region that alters susceptibility, and the mechanisms by which this occurs. The results of
this meta-analysis and of the aggregate analysis of multiple alleles reported in the ISC paper
strongly suggest that individual common variants have small effects on schizophrenia risk,
and that still larger samples may be valuable. The larger goal of research in the field will be
to detect and understand the full range of rare and common sequence and structural
schizophrenia susceptibility variants. Association findings will advance knowledge of
pathophysiological mechanisms, even if they initially explain small proportions of genetic
variance. Future advances in knowledge of gene and protein functions and interactions
should make it possible to dissect the functional sets of pathogenic variants based on prior
hypotheses.
Methods summary
Details of MGS subject recruitment and sample characteristics are provided in the online
Full Methods (section A1). DNA samples were genotyped using the Affymetrix 6.0 array at
the Broad Institute. Samples (5.3%) were excluded for high missing data rates, outlier
proportions of heterozygous genotypes, incorrect sex or genotypic relatedness to other
subjects. SNPs (7% for African American, 25% for European-ancestry and 27% for
combined analyses) were excluded for minor allele frequencies less than 1%, high missing
data rates, Hardy-Weinberg deviation (controls), or excessive Mendelian errors (trios),
discordant genotypes (duplicate samples) or large allele frequency differences among DNA
plates. Principal component scores reflecting continental and within-Europe ancestries of
each subject were computed and outliers excluded. Genomic control λ values for autosomes
after QC were 1.042 for African American and 1.087 for the larger European-ancestry and
combined analyses.
For MGS, association of single SNPs to schizophrenia was tested by logistic regression
(trend test) using PLINK10, separately for European-ancestry, African American and
combined datasets, correcting for principal component scores that reflected geographical
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gradients or that differed between cases and controls, and for sex for chromosome X and
pseudoautosomal SNPs. Genotypic data were imputed for 192 regions surrounding the best
findings, and for additional regions selected for meta-analysis.11 Detailed results are
available in Supplementary Datafiles 1 and 2, and complete results from dbGAP
(www.ncbi.nlm.nih.gov/sites/entrez?db=gap).
Meta-analysis of the MGS, ISC and SGENE datasets was carried out by combining P-values
for all SNPs (in the selected regions) for which genotyped or imputed data were available
for all datasets, with weights computed from case-control sample sizes. See the companion
papers for details of the ISC and SGENE analyses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the study participants, and the research staff at the study sites. This study was supported by funding from
the National Institute of Mental Health (U.S.A.) and the National Alliance for Research on Schizophrenia and
Depression. Genotyping of part of the sample was supported by the Genetic Association Information Network
(GAIN), and by The Paul Michael Donovan Charitable Foundation. Genotyping was carried out by the Center for
Genotyping and Analysis at the Broad Institute of Harvard and MIT with support from the National Center for
Research Resources (U.S.A.). The GAIN quality control team (G.R. Abecasis and J. Paschall) made important
contributions to the project. We thank S. Purcell for assistance with PLINK.
References
1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts"what we know in 2008. 2.
Epidemiology and etiology. Schizophr Res. 2008; 102:1–18. [PubMed: 18514488]
2. Cook EH Jr, Scherer SW. Copy-number variations associated with neuropsychiatric conditions.
Nature. 2008; 455:919–923. [PubMed: 18923514]
3. Arnold SE, Talbot K, Hahn CG. Neurodevelopment, neuroplasticity, and new genes for
schizophrenia. Progress in brain research. 2005; 147:319–345. [PubMed: 15581715]
4. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common
disease. J Clin Invest. 2008; 118:1590–1605. [PubMed: 18451988]
5. Adegbola A, Gao H, Sommer S, Browning M. A novel mutation in JARID1C/SMCX in a patient
with autism spectrum disorder (ASD). Am J Med Genet A. 2008; 146A:505–511. [PubMed:
18203167]
6. Costa E, et al. Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the
cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics. 2007; 2:29–
36. [PubMed: 17965595]
7. Kawasaki H, Iwamuro S. Potential roles of histones in host defense as antimicrobial agents.
Infectious disorders drug targets. 2008; 8:195–205. [PubMed: 18782037]
8. Malcherek G, et al. The B7 homolog butyrophilin BTN2A1 is a novel ligand for DC-SIGN. J
Immunol. 2007; 179:3804–3811. [PubMed: 17785817]
9. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to
pathways to pathogenesis. Nat Rev Genet. 2008; 9:516–526. [PubMed: 18542080]
10. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet. 2007; 81:559–575. [PubMed: 17701901]
11. Huang L, et al. Genotype-imputation accuracy across worldwide human populations. Am J Hum
Genet. 2009; 84:235–250. [PubMed: 19215730]
12. Wassink TH, et al. Evaluation of the chromosome 2q37.3 gene CENTG2 as an autism
susceptibility gene. Am J Med Genet B Neuropsychiatr Genet. 2005; 136B:36–44. [PubMed:
15892143]
Shi et al. Page 5
Nature. Author manuscript; available in PMC 2010 February 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Chromosome 6p22.1 Genetic association and linkage disequilibrium results in
European-ancestry samples
Genome-wide significant evidence for association (P < 5 × 10−8, threshold shown by solid
red line, SNPs by large red diamonds) was observed at 7 SNPs across 209 kb. P-values are
shown for all genotyped and imputed SNPs (25,900,000–27,875,000 bp) for the meta-
analysis of European-ancestry MGS, ISC and SGENE samples (8,008 cases, 19,077
controls). Red circles indicate other SNPs with P < 5 × 10−7. Not shown are two SNPs in
HLA-DQA1 (6p21.32; lowest P = 6.88 × 10−8, 32,710,247 bp; see Supplementary Datafile
1). Locations are shown for RefSeq genes and POM121L2. Pairwise LD relationships are
shown for 26 SNPs with P < 10−7 (except that SNPs 5 and 6 are shown, despite slightly
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larger P-values, to illustrate LD for that segment; and a SNP in strong LD with SNPs 25 and
26 is omitted). LD was computed from MGS European-ancestry genotyped and imputed
SNP data. The signal is poorly localized because of strong LD: of the 7 significant SNPs, 7–
8 and 9–11 are in nearly perfect LD; they are in or within ~ 30–50 kb of a cluster of 5
histone genes (HIST1H2BJ, HIST1H2AG, HIST1H2BK, HIST1H4I, HIST1H2AH;
27,208,073–27,223,325 bp). These SNPs are in moderately strong LD (r2 = 0.52–0.77) with
2 other significant SNPs 70–140 kb away, upstream of PRSS16 (SNP 13) or between
PRSS16 and POM121L2 (SNP18). (See Table 2 and Supplementary Figures S10–11 for
additional details.)
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